RehabilitationNCT06683963
AI-Assisted TelerehabiLitAtion System (ATLAS) for Post-discharge Continuation of Rehabilitative Care
A study testing Rebee in people with Rehabilitation and Deconditioning, run by SingHealth Community Hospitals.
Trial summary
The study team proposes ATLAS (AI-Assisted TelerehabiLitAtion System) a two-part solution. The first-Rebee AI-assisted telerehabilitation device-assists in inpatient rehabilitation, and allows patients to continue with their physical rehabilitation when discharged and waiting for Day Rehabilitation Centre (DRC). Read more about this study
- Who is it for?
- Ages 60 to 99 years
- Conditions the study is for
- Rehabilitation, Deconditioning
- What is being tested?
- Rebee
- Type of treatment
- Pill or oral medicine, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 450 participants
- Where
- No sites listed yet
- Study dates
- Dec 2024to Nov 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Rehabilitation Diagnostic Group (RDG): Total Knee Replacement / Deconditioning
- Age 60 and above
- Speak English/Mandarin
- Able to follow instructions, no cognitive impairment
- No MDRO (MultiDrug Resistant Organism)
- Suitable and able to wear motion sensor on upper and lower limbs
- Suitable and able to engage in Rebee exercises
Who cannot join
- Not under RDG: Total Knee Replacement / Deconditioning
- Below 60 years old
- Unable to speak English/Mandarin
- Cognitive impaired, unable to follow instructions
- Has MDRO
- Not suitable to wear motion sensor on upper and lower limbs
- Refusal to participate / give informed consent
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The study team proposes ATLAS (AI-Assisted TelerehabiLitAtion System) a two-part solution. The first-Rebee AI-assisted telerehabilitation device-assists in inpatient rehabilitation, and allows patients to continue with their physical rehabilitation when discharged and waiting for Day Rehabilitation Centre (DRC). The second-a structured programme to train and familiarise patients and caregivers to Rebee over patients' Community Hospital (CH) inpatient rehabilitation stay-adopts an evidence-based approach to increase uptake and adherence to Rebee.
- Conditions
- Rehabilitation, Deconditioning
- Being tested
- Rebee
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RebeeDevice
Tablet device with accompanying sensor device. Tablet device is preloaded with exercises, to be taught to patients during their hospital stay, and to be continued post-discharge
| Study group | Role | What they receive |
|---|---|---|
| Control - usual care | No intervention | Business as usual in community hospital, no added device intervention |
| Intervention - Rebee | Experimental | Addition of Rebee device during and after community hospital stay Receives: Device: Rebee |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Modified Barthel Index scores from baseline to 4, 8, and 12 weeks
Modified Barthel Index (MBI) measures ability to complete activities of daily living (ADLs).
Scores range from 0 to 100. A higher score represents more independence, a lower score indicates more assistance needed (ie less independent).
0-20: Total dependence, 21-60: Severe dependence, 61-90: Moderate dependence, 91-99: Slight dependence, 100: Independence.
Measured: from recruitment (week 0) till end of study at 12 weeks
Secondary outcomes (6)
Change in Quality of Life scores from baseline to 4, 8, and 12 weeks
Quality of Life as measured using EQ-5D-5L.
Has two components to this instrument:
- EQ-5D descriptive system
- 1 to 5 for each dimension
- A higher score represents "worse health status" (i.e., more severe problems with dimension).
- EQ visual analogue scale (EQ VAS)
- 0 to 100
- A higher score represents "better health status" (i.e., overall current health status).
Measured: from recruitment (week 0) till end of study at 12 weeks
Change in Patient Activation Level from baseline to 4, 8, and 12 weeks
Patient Activation Level measured using PAM-13 Score from 0 to 100 Higher scores indicate greater patient activation
Measured: from recruitment (week 0) till end of study at 12 weeks
Readmission rates to hospital within 30 days of discharge
e.g. 0 means no readmissions back to hospital within 30 days of discharge occured
Measured: within 30 days from discharge date
Change in Joint range of motion from baseline to 4, 8, and 12 weeks
Measured Joint Range of operated knee for patients with total knee replacement (TKR) Joint range will be measured for knee Extension and well as knee Flexion
Measured: from recruitment (week 0) till end of study at 12 weeks
Length of Stay in Community Hospital reported in days
Length of (inpatient) Stay in Community Hospital Reported in days, as measured by Discharge Date minus Admission Date e.g. if Discharge Date is 3/11/2024, and Admission Date is 1/11/2024, patient stayed for 2 days as an inpatient in the community hospital
Measured: From recruitment (week 0) till end of study at 12 weeks
Change in STS (sit to stand) score from baseline to 4, 8, and 12 weeks
Time taken to Sit to Stand 5 times, calculated in seconds A higher score represents taking a longer time to complete 5 times sit to stand.
Measured: from recruitment (week 0) till end of study at 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Nov 2024
- Study startDec 2024 (estimated)
- Primary completionNov 2025 (estimated)
- Study completionNov 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for RehabilitationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 450 participants (estimated)
Sponsor and investigators
- Lead sponsor
- SingHealth Community Hospitals
- Sponsor type
- University, hospital or other
- Collaborators
- Rebee Health, Jurong Community Hospital
- Responsible party
- Principal investigator, Low Lian Leng, SingHealth Community Hospitals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06683963
- Sponsor's protocol ID
- 20242246
- Status last verified
- Nov 2024
- First submitted
- 29 Oct 2024
- Last updated
- 12 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Tan CYM, Seah XY, Seah SSY, Loh XH, Chua WHP, Xia OJ, D/O Chandran C, Hosain H, Qiu W, Chong K, Tai BC, Low LL. Implementation and Evaluation of an AI-Assisted Telerehabilitation System for Postdischarge Continuation of Rehabilitative Care: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2026 Aug 5;15:e78400. doi: 10.2196/78400.
PubMed 42555956
Study at a glance
From the registry record, last updated by the sponsor on 12 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- AI-Assisted TelerehabiLitAtion System (ATLAS) for Post-discharge Continuation of Rehabilitative Care
- ClinicalTrials.gov ID
- NCT06683963
- Acronym / sponsor ID
- 20242246
- Conditions
- Rehabilitation, Deconditioning
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 450 participants (estimated)
- Lead sponsor
- SingHealth Community HospitalsUniversity, hospital or other
- Collaborators
- Rebee Health, Jurong Community Hospital
- Study start
- Dec 2024 (estimated)
- Primary completion
- Nov 2025 (estimated)
- Study completion
- Nov 2025 (estimated)
- First posted
- 12 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study team proposes ATLAS (AI-Assisted TelerehabiLitAtion System) a two-part solution. The first-Rebee AI-assisted telerehabilitation device-assists in inpatient rehabilitation, and allows patients to continue with their physical rehabilitation when discharged and waiting for Day Rehabilitation Centre (DRC). The second-a structured programme to train and familiarise patients and caregivers to Rebee over patients' Community Hospital (CH) inpatient rehabilitation stay-adopts an evidence-based approach to increase uptake and adherence to Rebee.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control - usual care | No intervention | –Business as usual in community hospital, no added device intervention |
| Intervention - Rebee | Experimental | Device: RebeeAddition of Rebee device during and after community hospital stay |
Who may qualify
- Ages
- 60 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Rehabilitation Diagnostic Group (RDG): Total Knee Replacement / Deconditioning
- Age 60 and above
- Speak English/Mandarin
- Able to follow instructions, no cognitive impairment
- No MDRO (MultiDrug Resistant Organism)
Key exclusion criteria (7 listed)
- Not under RDG: Total Knee Replacement / Deconditioning
- Below 60 years old
- Unable to speak English/Mandarin
- Cognitive impaired, unable to follow instructions
- Has MDRO
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RebeeTablet device with accompanying sensor device. Tablet device is preloaded with exercises, to be taught to patients during their hospital stay, and to be continued post-discharge | Device | Intervention - Rebee |
Primary outcome
Change in Modified Barthel Index scores from baseline to 4, 8, and 12 weeks
Time frame: from recruitment (week 0) till end of study at 12 weeks
Modified Barthel Index (MBI) measures ability to complete activities of daily living (ADLs). Scores range from 0 to 100. A higher score represents more independence, a lower score indicates more assistance needed (ie less independent). 0-20: Total dependence, 21-60: Severe dependence, 61-90: Moderate dependence, 91-99: Slight dependence, 100: Independence.
6 secondary outcomes
Change in Quality of Life scores from baseline to 4, 8, and 12 weeks
Time frame: from recruitment (week 0) till end of study at 12 weeks
Change in Patient Activation Level from baseline to 4, 8, and 12 weeks
Time frame: from recruitment (week 0) till end of study at 12 weeks
Readmission rates to hospital within 30 days of discharge
Time frame: within 30 days from discharge date
Change in Joint range of motion from baseline to 4, 8, and 12 weeks
Time frame: from recruitment (week 0) till end of study at 12 weeks
Length of Stay in Community Hospital reported in days
Time frame: From recruitment (week 0) till end of study at 12 weeks
Change in STS (sit to stand) score from baseline to 4, 8, and 12 weeks
Time frame: from recruitment (week 0) till end of study at 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Nov 2024.
- Derived from this study: PubMed 42555956Tan CYM, Seah XY, Seah SSY, Loh XH, Chua WHP, Xia OJ, D/O Chandran C, Hosain H, Qiu W, Chong K, Tai BC, Low LL. Implementation and Evaluation of an AI-Assisted Telerehabilitation System for Postdischarge Continuation of Rehabilitative Care: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2026 Aug 5;15:e78400. doi: 10.2196/78400.
- Individual participant dataSharing planned: No
Related trials for Rehabilitation
Recruiting
Cervical tsDCS on Stroke Patients
Functional Recovery, Motor Rehabilitation
Not yet recruiting
Accessible Remote Rehabilitation System for Real-Time Biomechanical Monitoring
Hand Injury Rehabilitation, Postoperative Rehabilitation
Recruiting
Transcranial Alternating Current Stimulation (tACS) Combined With Cognitive Training in Alzheimer's Disease
Transcranial Alternating Current Stimulation, Alzheimer Disease (AD)
Not yet recruitingEarly Phase 1
Early Botulinum Toxin for Muscle Stiffness Reduction in First-Time Stroke Patients: Improving Recovery and Independence
Spasticity, Stroke
RecruitingObservational study
Early Postoperative Pain Following a Limb Amputation
Amputation, Surgical, Pain Management
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Rebee in people with Rehabilitation and Deconditioning, run by SingHealth Community Hospitals.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 12 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lian Leng Low (+6563265872, low.lian.leng@singhealth.com.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Modified Barthel Index scores from baseline to 4, 8, and 12 weeks (time frame: from recruitment (week 0) till end of study at 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06683963, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Nov 2024; AzTrials last refreshed its copy on 8 Nov 2026.